Kala Bio (KALA) EBITDA (2016 - 2026)

Kala Bio has disclosed EBITDA across 11 years of filings, most recently posting -$1.7 million for Q2 2026.

• In Q2 2026, EBITDA rose 84.39% year-over-year to -$1.7 million; the TTM figure through Jun 2026 stood at -$21.0 million (up 48.99% YoY), while the FY2025 annual figure was -$39.2 million, up 4.45% from the prior year.
• EBITDA came in at -$1.7 million for Q2 2026 at Kala Bio, up from -$1.8 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$1.7 million in Q2 2026 to a low of -$30.9 million in Q1 2022.
• Average EBITDA over 5 years is -$11.4 million, with a median of -$10.1 million recorded in 2024.
• Year-over-year, EBITDA slipped 14.82% in 2025 and surged 84.39% in 2026.
• Over 5 years, EBITDA stood at -$10.3 million in 2022, then gained by 6.17% to -$9.6 million in 2023, then gained by 1.66% to -$9.5 million in 2024, then dropped by 8.1% to -$10.2 million in 2025, then jumped by 83.17% to -$1.7 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$1.7 million in Q2 2026, -$1.8 million in Q1 2026, and -$10.2 million in Q4 2025.